Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209154 | 0.78 | DRD4 (0.61) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL4559554 | 0.76 | DRD4 (0.43) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL4558670 | 0.76 | ALDH1A1 (0.50) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL4559492 | 0.76 | SIGMAR1 (0.46) | ALDH1A1SIGMAR1POLBCHRM2CHRM1 | |
| SCHEMBL7343072 | 0.74 | CACNA2D1 (0.53) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL7282542 | 0.72 | SIGMAR1 (0.58) | ALDH1A1SIGMAR1TP53CHRM2CHRM1 | |
| SCHEMBL28095554 | 0.72 | MEN1 (0.59) | ALDH1A1SIGMAR1DRD4CHRM2CHRM1 | |
| SCHEMBL27813496 | 0.71 | SIGMAR1 (0.42) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL4039571 | 0.70 | KMT2A (0.64) | ALDH1A1SIGMAR1POLB | |
| SCHEMBL7676221 | 0.70 | SIGMAR1 (0.56) | ALDH1A1SIGMAR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | CACNA2D1 3191/4885CACNA1B 1061/4885CACNB1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.